MSH2 deletion	Endometrial Adenocarcinoma	MSH2 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSH2 deletion	Prostate Cancer	MSH2 deletion	Prostate Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSH2 deletion	Urothelial Cancer	MSH2 deletion	Urothelial Cancer	durvalumab + MEDI0680 Sensitive: C4 – Case Studies durvalumab + MEDI0680 Sensitive : C4	durvalumab + MEDI0680 Sensitive: C4 – Case Studies durvalumab + MEDI0680 Sensitive : C4
MSH2 deletion	Glioblastoma	MSH2 deletion	Glioblastoma	temozolomide Resistant: D – Preclinical temozolomide Resistant : D	temozolomide Resistant: D – Preclinical temozolomide Resistant : D

MSH2 deletion

Associations